Clinical Trial Update: The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC [Phase 3]

View source ↗

Summary

Phase 3 BURAN study evaluating buparlisib in recurrent or metastatic head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Buparlisib (buparlisib)

Snippet

Sponsor: Adlai Nortye Biopharma Co., Ltd. | Conditions: Head and Neck Cancer | Phase 3 | Status: COMPLETED